Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Gross Margin for 7 consecutive years, with 82.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 182.0% year-over-year to 82.91%, compared with a TTM value of 85.19% through Dec 2025, down 81.0%, and an annual FY2025 reading of 85.19%, down 81.0% over the prior year.
  • Gross Margin was 82.91% for Q4 2025 at Catalyst Pharmaceuticals, down from 84.73% in the prior quarter.
  • Across five years, Gross Margin topped out at 88.35% in Q1 2023 and bottomed at 80.82% in Q4 2021.
  • Average Gross Margin over 5 years is 85.41%, with a median of 85.66% recorded in 2022.
  • The sharpest move saw Gross Margin plummeted -1509bps in 2021, then surged 413bps in 2023.
  • Year by year, Gross Margin stood at 80.82% in 2021, then rose by 1bps to 81.57% in 2022, then grew by 5bps to 85.7% in 2023, then fell by -1bps to 84.74% in 2024, then dropped by -2bps to 82.91% in 2025.
  • Business Quant data shows Gross Margin for CPRX at 82.91% in Q4 2025, 84.73% in Q3 2025, and 85.94% in Q2 2025.